Zytiga

C₂₄H₃₁NO349.50 g/mol

(3S,8R,9S,10R,13S,14S)-10,13-Dimethyl-17-pyridin-3-yl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-3-ol

Drag to rotate; arrow keys step through the atoms. Structure from PubChem CID 132971.

Registration

Applicants: 1
Registrations: 1

Applicants and registrations

Applicant	Brands	Dosages	Registrations	Schedule	Leaflets
Janssen Pharmaceutica (Pty) Ltd	Zytiga	250 mg	460379	Not determined	PI PIL

Variants

Product	Strength and form	Registration	Status	Schedule	Leaflets
Zytiga 250 MG EACH TABLET CONTAINS ABIRATERONE 250,0 mg	250 mg	46037946/21.12/0379	Registered	Not determined	PI PIL

Regulatory status

This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.

Listings for this ingredient that could not be applied to this product

S4: Abiraterone
Consolidated Schedules 06 July 2026, line 5131
S4: Niraparib
Consolidated Schedules 06 July 2026, line 7281

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

Background

Loading Wikipedia summary

SAHPRA documents

Professional information (PI)For healthcare professionalsZytiga 250 MG, Janssen Pharmaceutica (Pty) Ltd. SAHPRA's document for ZYTIGA Patient information leaflet (PIL)For patients and carersZytiga 250 MG, Janssen Pharmaceutica (Pty) Ltd. SAHPRA's document for ZYTIGA

These documents come from SAHPRA's PI-PIL repository unless the line under a document says otherwise. Always consult with a healthcare professional for medical advice.

Research articles

Loading PubMed articles